Efficacy and Safety of Disitamab Vedotin Plus Pyrotinib or Naratinib in HER2-positive Breast Cancer Patients With Brain Metastasis

NANot yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 30, 2023

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2027

Conditions
Breast Cancer
Interventions
DRUG

Disitamab Vedotin plus pyrotinib or naratinib

"Trastuzumab Injection: Intravenous infusion, initial loading dose of 2 mg/kg, administered via intravenous infusion over 30-90 minutes (usually recommended around 60 minutes), administered on day 1 of each cycle, with each cycle lasting 14 days.~Pyrotinib Maleate Tablets: 400 mg, taken orally once daily, within 30 minutes after a meal, at the same time every day. Taken continuously, with each cycle lasting 14 days.~Neratinib Maleate Tablets: 240 mg, taken orally once daily with a meal, at the same time every day. The neratinib tablet should be swallowed whole (it should not be chewed, crushed, or split before swallowing). Taken continuously, with each cycle lasting 14 days."

Trial Locations (1)

710100

Xi'an International Medical Center Hospital, Xi'an

All Listed Sponsors
lead

Xi'an International Medical Center Hospital

OTHER

NCT06015113 - Efficacy and Safety of Disitamab Vedotin Plus Pyrotinib or Naratinib in HER2-positive Breast Cancer Patients With Brain Metastasis | Biotech Hunter | Biotech Hunter